A Critical Analysis Please like and subscribe if you enjoyed this video Abstract The treatment landscape for managing weight in non-diabetic patients has changed dramatically with the introduction of glucagon-like peptide-1 (GLP-1) receptor agonists as anti-obesity drugs
Most patients report that discomfort is mild and manageable with rest, hydration, and over-the-counter pain relief
Despite these promising findings, it is important to emphasize that evidence supporting the use of retatrutide is currently limited to adult clinical trials
2,000+ licensed providers: One of the largest telehealth provider networks for GLP-1 weight loss programs
Ethics declarations Conflict of interest Bartlomiej Kwiek reported serving as a clinical study investigator for AbbVie, Amgen inc, Arcutis Biotherapeuthics, Almirall, Aslan, Bristol-Myers Squibb, Celdex Therapeutics, Celltrion, Dermira, Galderma, Glenmark, Incyte, Janssen Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Regeneron, Samsung